Literature DB >> 33599760

Counting the cost of caplacizumab.

Shruti Chaturvedi1.   

Abstract

Year:  2021        PMID： 33599760      PMCID： PMC7918185          DOI： 10.1182/blood.2020009250

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

Review 1.  TTP: long-term outcomes following recovery.

Authors:  James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Marie Scully; Spero R Cataland; Flora Peyvandi; Paul Coppo; Paul Knöbl; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Filip Callewaert; Debjit Biswas; Hilde De Winter; Robert K Zeldin
Journal:  N Engl J Med       Date:  2019-01-09       Impact factor: 91.245

Review 3.  How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns.

Authors:  Marshall A Mazepa; Camila Masias; Shruti Chaturvedi
Journal:  Blood       Date:  2019-06-19       Impact factor: 22.113

4.  Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Pranay Sinha; Jeanne E Hendrickson; Christopher Tormey; Pavan K Bendapudi; Alfred Ian Lee
Journal:  Blood       Date:  2021-02-18       Impact factor: 22.113

5.  Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.

Authors:  F Peyvandi; M Scully; J A Kremer Hovinga; P Knöbl; S Cataland; K De Beuf; F Callewaert; H De Winter; R K Zeldin
Journal:  J Thromb Haemost       Date:  2017-06-05       Impact factor: 5.824

6.  ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.

Authors:  Linus A Völker; Jessica Kaufeld; Wolfgang Miesbach; Sebastian Brähler; Martin Reinhardt; Lucas Kühne; Anja Mühlfeld; Adrian Schreiber; Jens Gaedeke; Markus Tölle; Wolfram J Jabs; Fedai Özcan; Silke Markau; Matthias Girndt; Frederic Bauer; Timm H Westhoff; Helmut Felten; Martin Hausberg; Marcus Brand; Jens Gerth; Markus Bieringer; Martin Bommer; Stefan Zschiedrich; Johanna Schneider; Saban Elitok; Alexander Gawlik; Anja Gäckler; Andreas Kribben; Vedat Schwenger; Ulf Schoenermarck; Maximilian Roeder; Jörg Radermacher; Jörn Bramstedt; Anke Morgner; Regina Herbst; Ana Harth; Sebastian A Potthoff; Charis von Auer; Ralph Wendt; Hildegard Christ; Paul T Brinkkoetter; Jan Menne
Journal:  Blood Adv       Date:  2020-07-14

7.  Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.

Authors:  Ygal Benhamou; Cyrielle Assié; Pierre-Yves Boelle; Marc Buffet; Rana Grillberger; Sandrine Malot; Alain Wynckel; Claire Presne; Gabriel Choukroun; Pascale Poullin; François Provôt; Didier Gruson; Mohamed Hamidou; Dominique Bordessoule; Jacques Pourrat; Jean-Paul Mira; Véronique Le Guern; Claire Pouteil-Noble; Cédric Daubin; Philippe Vanhille; Eric Rondeau; Jean-Bernard Palcoux; Christiane Mousson; Cécile Vigneau; Guy Bonmarchand; Bertrand Guidet; Lionel Galicier; Elie Azoulay; Hanspeter Rottensteiner; Agnès Veyradier; Paul Coppo
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

8.  The high cost of prescription drugs: causes and solutions.

Authors:  S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2020-06-23       Impact factor: 11.037
  8 in total
  2 in total

Review 1.  Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.

Authors:  H T Lim; B H Kok; C P Lim; A B Abdul Majeed; C Y Leow; C H Leow
Journal:  Biomed Eng Adv       Date:  2022-09-18

Review 2.  The standard of care for immune thrombotic thrombocytopenic purpura today.

Authors:  X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-06-30       Impact factor: 16.036
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.